Back to top
more

Adaptive Biotechnologies (ADPT)

(Delayed Data from NSDQ)

$5.82 USD

5.82
1,382,825

+0.19 (3.37%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $5.82 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Perrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales

by Zacks Equity Research

Perrigo (PRGO) reports mixed fourth-quarter 2022 results. While the company beats the mark on earnings, it misses sales estimates.

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q4

by Zacks Equity Research

Karuna Therapeutics (KRTX) reports encouraging fourth-quarter 2022 results. The company beats estimates for earnings and sales.

Can Adaptive Biotechnologies (ADPT) Climb 45.58% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Adaptive Biotechnologies (ADPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adaptive Biotechnologies (ADPT) and Geron (GERN) have performed compared to their sector so far this year.

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 24.32% and 1.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.51% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 7.50% and 0.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Adaptive Biotechnologies (ADPT) This Earnings Season?

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q3 sales.

CVS Health (CVS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Robust retail and pharmacy sales performance are likely to have driven CVS Health's (CVS) Q2 performance.

Earnings Preview: NGM Biopharmaceuticals (NGM) Q2 Earnings Expected to Decline

by Zacks Equity Research

NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -2.33% and 0.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Rises on Restructuring Plans

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) announces reorganization of its business around MRD and Immune Medicine to drive future growth. The company hires a market veteran in health care as its new CFO.

    Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 5.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Adaptive Biotechnologies (ADPT) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    After Plunging 46.4% in 4 Weeks, Here's Why the Trend Might Reverse for Adaptive Biotechnologies (ADPT)

    by Zacks Equity Research

    The heavy selling pressure might have exhausted for Adaptive Biotechnologies (ADPT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

    Bears are Losing Control Over Adaptive Biotechnologies (ADPT), Here's Why It's a 'Buy' Now

    by Zacks Equity Research

    After losing some value lately, a hammer chart pattern has been formed for Adaptive Biotechnologies (ADPT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

    Gamida (GMDA) Up on Omidubicel BLA Rolling Submission Plan

    by Zacks Equity Research

    The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.

    Vertex (VRTX) Kaftrio Gets Europe Nod for CF in Children

    by Zacks Equity Research

    The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.

    Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 6.98% and 4.97%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Adaptive Biotechnologies (ADPT) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 18.60% and 20.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: Adaptive Biotechnologies (ADPT) Q2 Earnings Expected to Decline

    by Zacks Equity Research

    Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Kevin Cook headshot

    Bull of the Day: Exact Sciences (EXAS)

    by Kevin Cook

    EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year